Dr. Mary T Jenkins Vogel, MD
Claim this profileNorthShore University HealthSystem-Evanston Hospital
Studies Cancer
Studies Ovarian Carcinoma
11 reported clinical trials
23 drugs studied
Area of expertise
1Cancer
Stage I
Stage IV
Stage III
2Ovarian Carcinoma
Stage I
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Mary T Jenkins Vogel, MD is currently running
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Letrozole +/- Chemotherapy
for Ovarian Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.
Recruiting2 awards Phase 318 criteria
More about Mary T Jenkins Vogel, MD
Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Mary T Jenkins Vogel, MD has experience with
- Carboplatin
- Paclitaxel
- Pembrolizumab
- Olaparib
- Cediranib Maleate
- Durvalumab
Breakdown of trials Mary T Jenkins Vogel, MD has run
Cancer
Ovarian Carcinoma
Lung Cancer
Endometrioid Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mary T Jenkins Vogel, MD specialize in?
Mary T Jenkins Vogel, MD focuses on Cancer and Ovarian Carcinoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Mary T Jenkins Vogel, MD currently recruiting for clinical trials?
Yes, Mary T Jenkins Vogel, MD is currently recruiting for 4 clinical trials in Evanston Illinois. If you're interested in participating, you should apply.
Are there any treatments that Mary T Jenkins Vogel, MD has studied deeply?
Yes, Mary T Jenkins Vogel, MD has studied treatments such as Carboplatin, Paclitaxel, Pembrolizumab.
What is the best way to schedule an appointment with Mary T Jenkins Vogel, MD?
Apply for one of the trials that Mary T Jenkins Vogel, MD is conducting.
What is the office address of Mary T Jenkins Vogel, MD?
The office of Mary T Jenkins Vogel, MD is located at: NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois 60201 United States. This is the address for their practice at the NorthShore University HealthSystem-Evanston Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.